Stock INIT INITIATOR PHARMA A/S
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Initiator Pharma A/S

Equities

INIT

DK0060775872

Delayed Nasdaq Stockholm
Other stock markets
 13:10:18 13/05/2024 BST 		5-day change 1st Jan Change
9.2 SEK 0.00% Intraday chart for Initiator Pharma A/S -2.34% -0.43%
05-10 Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
02-23 Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024
Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Initiator Pharma Issues New Shares for Debt Conversion
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Initiator Pharma A/S Announces Positive Results from Phase IIb Clinical Trial with Pudafensine
Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction
Initiator Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Initiator Pharma A/S Obtains IP 2018 Patent in Europe for Treatment of Erectile Dysfunction and Depression
Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial
Initiator Pharma A/S (OM:INIT) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on May 26, 2023.
Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine
Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction
Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2023
Initiator Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2022
Initiator Pharma A/S Completes Dosing in Phase 2a Trial with IP2018
Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Initiator Pharma A/S Provides an Update on Its Clinical Programs
Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INIT Stock
  4. News Initiator Pharma A/S
  5. Other languages